Skip to contentE
Enveric Biosciences, Inc.
E
ENVBEnveric Biosciences, Inc. Q3 2023 · 10-Q
Revenue—
Net Income-$2.82M-$2.82MN/M vs Q3 2022 EPS Diluted-$1.30-$1.30N/M vs Q3 2022 Operating Income-$3,448,395N/M Operating Cash Flowderived-$2,740,433N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Enveric Biosciences, Inc. · CIK 890821 · Engraved from SEC EDGAR
Free Cash Flowderived-$2,740,441N/M ended Sep 30, 2023 · filed Nov 13, 2023 · 44 d after period end